Other Events ·
Galmed Pharmaceuticals announced the development of a new orally dispersible film (ODF) formulation of its SCD1…
GLMDGalmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals announced the development of a new orally dispersible film (ODF) formulation of its SCD1 inhibitor Aramchol for Parkinson’s disease. The formulation demonstrates approximately 150% higher systemic bioavailability and a 300% increase in central nervous system exposure compared to conventional oral administration. This technology aims to improve patient adherence by addressing dysphagia, a common challenge in Parkinson's patients. The company positions Aramchol as a potential out-licensing candidate for the global Parkinson’s therapeutics market, valued at over $6 billion. Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical and medical device company focused on developing innovative solutions for gastrointestinal, cardiometabolic, and oncology indications.